ProTom International, Inc.

ProTom International, Inc. is a medical technology company focused on developing advanced proton therapy systems to enhance cancer treatment accessibility for healthcare providers globally. Founded in 2008 in Flower Mound, US, ProTom International, Inc. specializes in proton therapy systems.

The company has executed 3 deals with the most recent funding round occurring in April 2017, raising USD 30 mn. The leadership includes CEO Bill Behnke and Stephen Spotts, guiding the company’s strategic focus and operations. ProTom International specializes in the development and provision of advanced proton therapy systems, particularly the Radiance 330® Proton Therapy System. This system enhances cancer treatment accessibility through its modular and compact design, allowing integration into existing radiation oncology departments.

The Radiance 330® features various configurations including 180-degree and 360-degree rotating gantries, fixed beam rooms, and upright patient positioning systems. Its advanced pencil beam scanning technology and compact synchrotron particle accelerator enable treatment energy ranging from 70 MeV to 250 MeV, with future potential for proton imaging capabilities up to 330 MeV. ProTom caters to healthcare providers and oncology departments across North America, Europe, and Asia, where demand for innovative cancer treatment solutions is high. ProTom International generates revenue through the sale and deployment of the Radiance 330® Proton Therapy System and associated services.

The business operates primarily through B2B transactions with healthcare institutions, involving direct purchases or long-term partnerships. Revenue arises from the initial sale of systems as well as ongoing maintenance and upgrade services. Contracts are customized to suit specific oncology department needs, reflecting the complexity and modularity of the system. ProTom International plans to leverage its recent funding of USD 30 mn raised in April 2017 to support product development and market expansion.

Upcoming products include enhancements to the Radiance 330® system with potential new features planned for release in the next two years. The company aims to expand into new markets, particularly targeting regions in Asia and Europe by 2025, to meet the increasing global demand for advanced cancer treatment technologies.